Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Ibogaine Clinical Trials topic
No spam. Unsubscribe anytime.
Senate panel hears emotional testimony on bill to join multistate ibogaine trials; safety and funding questioned
Summary
The committee heard testimony from a veteran and advocates supporting Tennessee's participation in FDA-approved ibogaine clinical trials; members probed safety (cardiac monitoring), Schedule I research permissions, and the requested $5 million match and revenue-sharing model.
The Senate Health & Welfare Committee debated a proposal to allow Tennessee to join multistate FDA-approved clinical trials of ibogaine as a potential treatment for opioid use disorder and PTSD.
Sponsor presented the Hope Treatment Act, including an amendment that became the bill, saying the legislation would authorize participation in a multistate clinical-trial consortium and create a Tennessee Mental Health Innovation Fund with safeguards and a matching-fund requirement. "It does not change drug classification, doesn't expand public access, and does not bypass the FDA approval process," the sponsor said while describing a council structure intended to preserve legislative oversight.
Witness testimony included personal and expert accounts. Alex West, a retired Navy SEAL who said he received ibogaine treatment abroad, testified: "The 14 hour Ibogaine experience was so grueling but it saved my life." Ricky Harris of Tennessee Voices described the need to expand research and build Tennessee's research capacity. Brian Hubbard of Americans for Ibogaine outlined plans to anchor trials at academic centers and argued for public-private partnerships and commercialization returns to the state.
Committee members repeatedly raised clinical and legal questions: how to provide medical supervision for a Schedule I substance, cardiac safety protocols, the role of FDA-approved trial mechanisms, and where the requested $5 million would come from. Witnesses and counsel said Texas has already moved forward and drug developers would be expected to match state investments and provide a baseline royalty (contract language required at least 2% return to the state in one section). Members also discussed a supplemental $5 million request that advocates said would be needed to participate alongside Texas.
The committee adopted the amendment and later voted to move the bill to finance for further consideration of funding mechanics. The hearing left clinical efficacy claims as testimonial; questions about safety protocols and funding sources remain under review.
